Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Age-related increase in plasma p-tau217 in amyloid-beta-negative cognitively unimpaired individuals affects diagnostic interpretation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mammel Anna E, Gonzalez-Ortiz Fernando, Mousavi Ali, Hallett Kelsey, Encarnacion Mary, Biehl Don, Gill Pradip, Ismael Sazan, Fowler Christopher, Doecke James D, Ward Larry, Frykman Hans
Аннотация
INTRODUCTION: The extent to which non-pathological aging influences plasma biomarkers remains unclear. Here, we investigate factors influencing plasma p-tau217 levels in cognitively unimpaired (CU), amyloid-beta-negative (Aβ-) individuals.
METHODS: Plasma p-tau217 was measured in CU Aβ- positron emission tomography-negative (PET-) participants using two immunoassays (ALZpath n = 360 and LUMIPULSE G1200 n = 73). Associations between p-tau217 and age groups (60-69, 70-79, and 80+ years), apolipoprotein E (APOE) genotype, and gender were evaluated.
RESULTS: ALZpath plasma p-tau217 showed a non-pathological age-related increase (p < 0.001), and increased percentage within the intermediate zone with age. Lumipulse p-tau217 showed an increase in the percentage of subjects with positive results with age, however, this trend was not significant (p > 0.05). Men had higher levels of p-tau217 only with the ALZpath assay (p = 0.02; Lumipulse: p = 0.81). No significant associations were found between p-tau217 and APOE genotype.
DISCUSSION: Our results highlight the importance of incorporating age and sex into the interpretation of plasma p-tau217 particularly in preclinical stages.
METHODS: Plasma p-tau217 was measured in CU Aβ- positron emission tomography-negative (PET-) participants using two immunoassays (ALZpath n = 360 and LUMIPULSE G1200 n = 73). Associations between p-tau217 and age groups (60-69, 70-79, and 80+ years), apolipoprotein E (APOE) genotype, and gender were evaluated.
RESULTS: ALZpath plasma p-tau217 showed a non-pathological age-related increase (p < 0.001), and increased percentage within the intermediate zone with age. Lumipulse p-tau217 showed an increase in the percentage of subjects with positive results with age, however, this trend was not significant (p > 0.05). Men had higher levels of p-tau217 only with the ALZpath assay (p = 0.02; Lumipulse: p = 0.81). No significant associations were found between p-tau217 and APOE genotype.
DISCUSSION: Our results highlight the importance of incorporating age and sex into the interpretation of plasma p-tau217 particularly in preclinical stages.